Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.85) per share. This is a 90.51 percent increase over losses of $(8.96) per share from the same period last year.
Cowen & Co. Downgrades Credo Technology Group to Market Perform, Announces $11 Price Target
Cowen & Co. analyst Matt Ramsay downgrades Credo Technology Group (NASDAQ:CRDO) from Outperform to Market Perform and announces $11 price target.